George Henry Poste, D.V.M., Ph.D, D.Sc., F.R.S.

66 Years Old Born: c. 4/30/1944

Divorced 2/26/2007

Residence Cave

Creek, AZ

Gender: Male Race or Ethnicity: White Occupation: Biologist, Business Nationality: England Executive summary: Health Technology Networks Medical School: DVM, Bristol University Medical School: PhD Virology, Bristol University Professor: Research Professor, University of Pennsylvania Fellow: Pembroke College, Cambridge University Fellow: University College London Administrator: Director, Arizona Biodesign Institute, Arizona State University Health Technology Networks CEO (1999-) SmithKline Beecham Chief Science & Technology Officer and President of R&D (1992-99) Member of the Board of AdvancePCS (2002-) Member of the Board of Anacor Pharmaceuticals Member of the Board of Caremark Rx (2004-?) Member of the Board of Caris Diagnostics (2004-?) Member of the Board of diaDexus (as Chairman 1997-2004) Member of the Board of Exelixis, Inc. Member of the Board of Illumina Member of the Board of Maxygen Member of the Board of Monsanto (2003-) Member of the Board of Orchid Cellmark, Inc. Member of the Board of SmithKline Beecham (1992-99) Member of the Board of Structural GenomiX (2000-04) US Defense Department Defense Science Board Academy of Medical Sciences (UK) Fellow Council on Foreign Relations Hoover Institution Fellow Institute of Medicine Forum on Microbial Threats Molecular Profiling Institute Board of Directors National Academy of Sciences Working Group on Biological Weapons Royal College of Pathologists Royal Society Financial Times Columnist Cancer and Metastasis Reviews Co-Founder Advanced Drug Delivery Reviews Co-Founder Nature BioTechnology Editorial Board Commander of the British Empire

Director Exelixis, Inc. South San Francisc , CA Sector: HEALTHCARE / Biotechnology Director , Monsanto Company St. Louis , MO Sector: BASIC MATERIALS / Agricultural Chemicals George Poste, D.V.M., Ph.D., FRS, age 65, has been a director since August 2004. Since February 2009, Dr. Poste has been the Chief Scientist at Complex Adaptive Systems Initiative and Regents? Professor and Del E. Webb Professor of Health Innovation at Arizona State University. From May 2003 to February 2009, Dr. Poste served as the director of the Biodesign Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare, since 2000. From 1992 to 1999, he was the Chief Science and Technology Officer and President, R&D of SmithKline Beecham Corporation, a pharmaceutical company. Dr. Poste serves on the Defense Science Board of the U.S. Department of Defense (and chairs the Task Force on Bioterrorism) and is a member of other organizations dedicated to advance the defense against bioweapons and biowarfare. Since February 2003, Dr. Poste has served as a member of the board of directors of Monsanto Company, a publicly-held provider of agricultural products and solutions. From April 2000 until August 2009, Dr. Poste served as the Non-Executive Chairman of Orchid Cellmark, Inc., a publicly-held DNA forensics company. Dr. Poste currently serves as the Vice Chairman and Chief Scientific Advisor for Caris Life Sciences, a privately held medical diagnostics company. Dr. Poste is a Fellow of the Royal Society, the UK Academy of Medical Sciences, Hoover Institution, Stanford University, and various other prestigious organizations and has been awarded honorary doctorates from several universities. Dr. Poste holds a D.V.M. in veterinary medicine and a Ph.D. in Virology from the University of Bristol, England. Our Board of Directors has concluded that Dr. Poste should continue to serve as a director of Exelixis as of the date of this Proxy Statement due to particularly to his training as a scientist, his knowledge and experience with respect to the life sciences, healthcare and pharmaceutical industries, his broad leadership experience resulting from service on various boards, and his knowledge and experience with policymaking, regulatory issues and other governmental matters. Dr. Poste is the vice chairman of Caris Life Sciences and chief scientific advisor. In addition, he is chief scientist, Complex Adaptive Systems Initiative (CASI) at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine. From 2003 to 2008 he founded the Biodesign Institute at ASU (www.biodesign.asu.edu/). In creating this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. In addition to his academic post he serves as chief executive of a consulting company, Health Technology Networks, which specializes in the application of genomic technologies and computing in healthcare. He is chairman of Orchid Biosciences, the leading company in DNA forensic analysis, and serves on the board of directors of Monsanto, Exelixis and Caris. From 1992 to 1999 he was chief science and technology officer and president, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as R&D Scientist of the Year by

R&D Magazine and in 2006 he received the Einstein award from the Global Business Leadership
Council.

He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international security. He is a fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a distinguished fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He is a member of the US Defense Science Board, Institute of Medicine Forum on Global Health, and Council for Foreign Relations. He is chair of the DOD Task Force on Bioterrorism and the newly launched DOD Task Force on Synthetic Biology. George Poste, D.V.M., Ph.D., FRS, has been a director since August 2004. Since February 2009, Dr. Poste has been the Chief Scientist at Complex Adaptive Systems Initiative and Regents' Professor and Del E. Webb Professor of Health Innovation at Arizona State University. From May 2003 to February 2009, Dr. Poste served as the director of the Biodesign Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare, since 2000. From 1992 to 1999, he was the Chief Science and Technology Officer and President, R&D of SmithKline Beecham Corporation, a pharmaceutical company. Dr. Poste serves on the Defense Science Board of the U.S. Department of Defense (and chairs the Task Force on Bioterrorism) and is a member of other organizations dedicated to advance the defense against bioweapons and biowarfare. Since February 2003, Dr. Poste has served as a member of the board of directors of Monsanto Company, a publicly-held provider of agricultural products and solutions. From April 2000 until August 2009, Dr. Poste served as the Non-Executive Chairman of Orchid Cellmark, Inc., a publicly-held DNA forensics company. Dr. Poste currently serves as the Vice Chairman and Chief Scientific Advisor for Caris Life Sciences, a privately held medical diagnostics company. Dr. Poste is a Fellow of the Royal Society, the UK Academy of Medical Sciences, Hoover Institution, Stanford University, and various other prestigious organizations and has been awarded honorary doctorates from several universities. Dr. Poste holds a D.V.M. in veterinary medicine and a Ph.D. in Virology from the University of Bristol, England. Dr. George Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI) (http://www.casi.asu.edu/), Regents Professor and Del E. Webb Chair in Health Innovation at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine. He founded the Biodesign Institute at ASU (www.biodesign.asu.edu/) and served as Director for 2003 to 2009. In creating this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $300 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. He serves on the Board of Directors of Monsanto (since 2003), Exelixis (since 2004), Caris Life Sciences (since 2005), and the Scientific Advisory Board of Synthetic Genomics (since 2009). From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as R&D Scientist of the Year by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in 2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry. He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international healthcare and security. He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He served as a member of the Defense Science Board from 2003 to 2009 and Health Board of the US

Department of Defense (DoD) and is currently a member of the US Institute of Medicine Board on Global Health. He has served as a member of Advisory Committees for multiple U.S. Government Agencies in areas of defense, national security and healthcare. About Dr. George Poste serves as Chief Executive Officer of consulting company, Health Technology Networks, which specializes in the application of genomic technologies and computing in healthcare. History Dr. Poste assumed Directorship of The Complex Adaptive Systems Initiative (CASI) (http://www.casi.asu.edu/) in March 2009 (ASU announces new research initiative July 14, 2008, George Poste, director of the Biodesign Institute July 14, 2008, will lead the new Complex Adaptive Systems Initiative at ASU July 14, 2008 Poste to lead transformational initiative at ASU July 25, 2008). This program links expertise across the university in research on synthetic biology, ubiquitous sensing, healthcare informatics for personalized medicine and advanced computing for non-linear dynamics. From 2003 to 2009 he was Director of the Biodesign Institute at ASU (www.biodesign.asu.edu/). In leading this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering (Biodesign Institute Accomplishments).In addition to his academic post he serves on the Board of Directors of Monsanto (since February 2003), Exelixis (since August 2004), Caris Life Sciences (since 2005), and the Scientific Advisory Board of Synthetic Genomics. From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as R&D Scientist of the Year by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in 2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry. He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international security. He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. From 2003 to 2009 he was a member of the Defense Science Board of the US Department of Defense (DoD). He continues to serve on US government advisory boards related to national security, intelligence, terrorism and healthcare. He is a member of the US Institute of Medicine Board on Global Health. His personal interests are in automobile racing, military history, photography and exploring the deserts of the American Southwest.